{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=29", "query": { "condition": "Recurrent Ovary Cancer", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 765, "total_pages": 77, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Ovary+Cancer&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T15:48:30.430Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00006391", "title": "Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-04-05", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006391" }, { "nct_id": "NCT05039801", "title": "IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Endometrial Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Ovarian Clear Cell Adenocarcinoma", "Chondrosarcoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Recurrent Ovarian High Grade Serous Adenocarcinoma", "Refractory Endometrial Carcinoma", "Refractory Head and Neck Squamous Cell Carcinoma", "Refractory Melanoma", "Refractory Ovarian Clear Cell Adenocarcinoma", "Refractory Ovarian High Grade Serous Adenocarcinoma", "Stage III Ovarian Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Glutaminase-1 Inhibitor IACS-6274", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-09-30", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05039801" }, { "nct_id": "NCT02646319", "title": "Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Advanced Malignant Neoplasm", "Cervical Squamous Cell Carcinoma", "Endometrial Carcinoma", "Malignant Uterine Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Malignant Neoplasm", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Solid Neoplasm", "Stage III Bladder Cancer", "Stage III Prostate Cancer", "Stage III Renal Cell Cancer", "Stage IIIA Breast Cancer", "Stage IIIA Cervical Cancer", "Stage IIIA Ovarian Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Cervical Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Ovarian Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Renal Cell Cancer", "Stage IVA Bladder Cancer", "Stage IVA Cervical Cancer", "Stage IVB Bladder Cancer", "Stage IVB Cervical Cancer" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nanoparticle Albumin-Bound Rapamycin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2016-01", "completion_date": "2018-04-24", "has_results": false, "last_update_posted_date": "2019-06-06", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02646319" }, { "nct_id": "NCT04267575", "title": "Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Recurrent Malignant Solid Neoplasm", "Stage IV Breast Cancer", "Stage IV Prostate Cancer", "Stage IV Pancreatic Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Cancer", "Stage IV Fallopian Tube Cancer", "Stage IV Colon Cancer", "Stage IV Colorectal Cancer", "Stage IV Liver Cancer", "Stage IV Renal Cell Cancer", "Stage IV Rectal Cancer", "Stage IV Lung Cancer", "Stage IV Small Intestinal Cancer", "Stage IV Gastric Cancer", "Stage IV Bladder Cancer" ], "interventions": [ { "name": "Canady Helios Cold Plasma Scalpel", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Jerome Canady, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2019-07-30", "completion_date": "2023-04-14", "has_results": true, "last_update_posted_date": "2021-08-09", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267575" }, { "nct_id": "NCT01281514", "title": "A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Peritoneal Cavity Cancer", "Recurrent Ovarian Epithelial Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2010-12-14", "completion_date": "2018-01-08", "has_results": false, "last_update_posted_date": "2019-07-11", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281514" }, { "nct_id": "NCT02315430", "title": "Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Ovarian Clear Cell Adenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 13, "start_date": "2015-04-01", "completion_date": "2019-02-09", "has_results": true, "last_update_posted_date": "2020-03-10", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 410, "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 275 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315430" }, { "nct_id": "NCT01079832", "title": "Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Sarcoma", "Ovarian Stromal Cancer", "Recurrent Cervical Cancer", "Recurrent Endometrial Carcinoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Recurrent Uterine Sarcoma", "Recurrent Vaginal Cancer", "Recurrent Vulvar Cancer", "Stage III Cervical Cancer", "Stage III Endometrial Carcinoma", "Stage III Ovarian Epithelial Cancer", "Stage III Ovarian Germ Cell Tumor", "Stage III Uterine Sarcoma", "Stage III Vaginal Cancer", "Stage III Vulvar Cancer", "Stage IV Endometrial Carcinoma", "Stage IV Ovarian Epithelial Cancer", "Stage IV Ovarian Germ Cell Tumor", "Stage IV Uterine Sarcoma", "Stage IV Vulvar Cancer", "Stage IVA Cervical Cancer", "Stage IVA Vaginal Cancer", "Stage IVB Cervical Cancer", "Stage IVB Vaginal Cancer" ], "interventions": [ { "name": "stereotactic radiosurgery", "type": "RADIATION" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 50, "start_date": "2009-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-11-28", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01079832" }, { "nct_id": "NCT00005049", "title": "Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer", "Gastric Cancer", "Gastrointestinal Carcinoid Tumor", "Gastrointestinal Stromal Tumor", "Ovarian Cancer", "Peritoneal Cavity Cancer", "Small Intestine Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "floxuridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "1997-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-04-06", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005049" }, { "nct_id": "NCT00562185", "title": "Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "FEMALE", "summary": "18 Years to 120 Years · Female only" }, "enrollment_count": 0, "start_date": "2008-05", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2017-11-20", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00562185" }, { "nct_id": "NCT01223235", "title": "Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fallopian Tubes Cancer", "Ovarian Cancer", "Peritoneal Cancer" ], "interventions": [ { "name": "bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "2010-10", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2018-06-12", "last_synced_at": "2026-10-30T15:48:30.430Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01223235" } ] }